New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
12:23 EDTTKPYY, FURXFuriex confirms Takeda's NDA submission for Trelagliptin Succinate in Japan
Furiex Pharmaceuticals (FURX) confirmed that Takeda Pharmaceutical Company Limited (TKPYY) announced that it has submitted a New Drug Application, or NDA, to the Japanese Ministry of Health, Labour and Welfare for trelagliptin succinate, a once weekly dosage treatment for type 2 diabetes. Under Furiex’s agreement with Takeda, Furiex is eligible to receive royalties and sales-based milestones if trelagliptin succinate is approved and marketed in Japan.
News For FURX;TKPYY From The Last 14 Days
Check below for free stories on FURX;TKPYY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for FURX;TKPYY

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use